Despite various meta-analyses evaluating the effectiveness of NET and NCT in breast cancer, such as those by Wang et al., which highlight the superior tumor response with NCT in hormone receptor-positive cases, and by Huang et al., who support the continued recommendation of NCT despite NET's benefits, few studies compared the effectiveness of NCET and NET/NCT. This evidence concerns the gene NR4A1 and breast carcinoma.